What is KNSA's health score?

Kiniksa Pharmaceuticals International, plc (KNSA) has a TradeApes health score of 58 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is KNSA's estimated fair value?

Based on our 5-year discounted cash flow model, Kiniksa Pharmaceuticals International, plc's estimated fair value is $28.55 per share, representing a -42.0% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is KNSA undervalued or overvalued?

Our model currently rates KNSA as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for KNSA... Refresh in a moment for the full analysis.

Kiniksa Pharmaceuticals International, plc (KNSA)

Healthcare Overvalued low mixed

$49.23

Updated: 2026-06-05

TradeApes Score

Financial Strength

80 Strong

Operating Trend

55 Mixed

Relative Value

35 Weak

Capital Allocation

50 Mixed

Risk

80 Strong

Est. Fair Value $28.55

DCF Upside -42.0%

Sector Rank #6 of 6820

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Extreme P/E — above 45×, very high expectations embedded in price

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.